Related Experiment Video
Updated: Jul 5, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?
1Department of Pathology, Pathologic/Cytologic Clinic, University Hospital of Lund, 221 85 Lund, Sweden. dorthe.grabau@skane.se
Abstract:
Women with breast cancer and micrometastases only constitute a treatment dilemma. If only a micrometastasis is found in a sentinel lymph node, an axillary lymph node dissection may be considered to be overtreatment and perhaps could be avoided. However, studies have shown decreased survival in patients with micrometastases only. This paper focuses on the pathological work-up behind the classification of breast cancer patients having micrometastases only and on the most recent literature concerning prognosis for breast cancer patients with micrometastases. The goal was to determine if studies to date have been able to define a population of breast cancer patients with micrometastases where the size of the metastasis could indicate whether an axillary lymph node dissection should be undertaken. Tailored surgical treatment of breast cancer patients with micrometastases only is not possible at the present time, due to lack of standardization in the pathological work-up of lymph nodes, which implies that this group of breast cancer patients cannot be delimited with sufficient precision. Tailored systemic therapy is also impossible due to lack of a precisely defined target for a feasible therapy.
Insights
Accurate pathological assessment of breast cancer micrometastases is crucial for treatment decisions. Current diagnostic methods lack standardization, preventing precise patient stratification and tailored therapies for improved survival outcomes.
Area of Science:
- Oncology
- Pathology
- Surgical Oncology
Background:
- Breast cancer patients with only micrometastases present a treatment challenge.
- Sentinel lymph node micrometastases raise concerns about overtreatment with axillary lymph node dissection.
- Existing literature indicates reduced survival rates for patients with micrometastases only.
Purpose of the Study:
- To examine the pathological work-up for classifying breast cancer patients with micrometastases.
- To review current literature on the prognosis of breast cancer patients with micrometastases.
- To determine if metastasis size can guide decisions on axillary lymph node dissection.
Main Methods:
- Review of pathological classification standards for lymph node micrometastases.
- Analysis of recent scientific literature on breast cancer micrometastasis prognosis.
- Evaluation of studies correlating metastasis size with treatment outcomes.
Main Results:
- Lack of standardization in lymph node pathological work-up hinders precise delimitation of patients with micrometastases.
- Current pathological methods do not allow for accurate definition of the patient population with micrometastases.
- Tailored surgical and systemic treatment approaches are not feasible due to imprecise patient stratification.
Conclusions:
- Standardization of pathological lymph node assessment is essential for precise patient classification.
- Improved diagnostic precision is needed to enable tailored surgical and systemic therapies for breast cancer patients with micrometastases.
- Further research is required to define criteria for guiding axillary lymph node dissection in cases of micrometastasis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...